2022
DOI: 10.1080/10717544.2022.2080889
|View full text |Cite
|
Sign up to set email alerts
|

A non-invasive direct nose to brain drug delivery platform vs. invasive brain delivery approach: patient-centered care impact analysis

Abstract: Current literature lacks structured methodologies for analyzing medical technologies’ impact from the patient-centered care perspective. This study introduces, applies and validates ‘Patient-Centered Care Impact Analysis’ (PCIA) as a method for identifying patient-centered care associated demands and expectations for a particular technology and assessing its compliance with these demands. PCIA involves five stages: (1) demand identification, (2) ranking demands’ impact magnitude, (3) scoring demand compliance … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
5
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
4
1

Relationship

2
3

Authors

Journals

citations
Cited by 6 publications
(5 citation statements)
references
References 20 publications
0
5
0
Order By: Relevance
“…We selected the SipNose product due to its unique approach to intranasal drug delivery. The SipNose product differs from existing methods since it takes advantage of the nasal cavity's physio-anatomy that allows efficient drug absorption and delivery directly to the brain [ 35 ]. Existing, commercially available intranasal drug-delivery devices deliver aerosol mainly to the lower and mid-nasal cavity turbinates and only minor amounts if any to the upper nasal cavity turbinates, thus allowing systemic delivery via the vascular rich mucosa in the middle-turbinate region.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…We selected the SipNose product due to its unique approach to intranasal drug delivery. The SipNose product differs from existing methods since it takes advantage of the nasal cavity's physio-anatomy that allows efficient drug absorption and delivery directly to the brain [ 35 ]. Existing, commercially available intranasal drug-delivery devices deliver aerosol mainly to the lower and mid-nasal cavity turbinates and only minor amounts if any to the upper nasal cavity turbinates, thus allowing systemic delivery via the vascular rich mucosa in the middle-turbinate region.…”
Section: Discussionmentioning
confidence: 99%
“…In fact, due to its direct CNS tissue delivery, lower doses are needed when compared with systemic delivery [ 33 , 34 ]. Furthermore, in a recent study, Kobo-Greenhut, et al highlight the qualitative clinical advantages of intranasal direct nose-to-brain delivery over invasive intrathecal and intracerebroventricular CNS drug delivery [ 35 ]. SipNose is one such non-invasive direct nose-to-brain (DNTB) drug delivery platform [ 35 ] (see Fig.…”
Section: Introductionmentioning
confidence: 99%
“…The SipNose product differs from existing methods since it takes advantage of the nasal cavity's physio-anatomy that allows e cient drug absorption and delivery directly to the brain. 41 Existing, commercially available intra-nasal drug-delivery devices deliver aerosol mainly to the lower and mid turbinate of the nasal cavity and only minor amounts to the upper turbinate of the nasal cavity, thus allowing systemic delivery via the rich blood capillaries' mucosa in the middle-turbinate area in the nasal cavity. In contrast, SipNose technology changes the ratios and delivers percentages of the aerosol to the upper turbinate, thus allowing limited systemic circulation delivery and pronounced direct delivery from the olfactory epithelium to the brain.…”
Section: Discussionmentioning
confidence: 99%
“…As such, they maintain comparable limitations to the oral route. SipNose is a novel non-invasive direct nose-to-brain (DNTB) drug delivery platform that delivers drugs to the central nervous system (CNS) 41 (see Fig. 1).…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation